Review clinical evidence: Somatrogon in PGHD IN PEDIATRIC GHD PATIENTS WITH NEW TREATMENT OPTIONS

Speciality: Pediatrics

Description:

A warm welcome to all the medical professionals in this interesting session on Review clinical evidence: Somatrogon in PGHD IN PEDIATRIC GHD PATIENTS WITH NEW TREATMENT OPTIONS
Somatrogon, a long-acting growth hormone, has emerged as a promising treatment for pediatric growth hormone deficiency (PGHD). Clinical trials have demonstrated its efficacy in promoting growth in children with GHD, offering a new treatment option that requires fewer injections compared to traditional daily growth hormone therapies. This convenience can significantly improve treatment adherence and quality of life for both patients and caregivers.
Reviewing clinical evidence, studies have shown that Somatrogon is well-tolerated and effective in stimulating height velocity in children with PGHD. The reduced injection frequency (once-weekly) makes it an attractive alternative to daily injections, without compromising therapeutic outcomes. These findings offer hope for better compliance and long-term success in managing pediatric GHD.
Therefore, get an overall knowledge of Review clinical evidence: somatrogon in PGHD in pediatrics ghd patients with new treatment options. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars